Schizophrenic patients and healthy controls participated in event-related potential experiments, in which illusory contour (IC) and control objects [no contour (NC), real contour (RC)] were passively presented. As a result, P100 latency for IC in schizophrenic patients was significantly prolonged (+10.6 ms) compared to those for RC. The present findings indicate that an abnormality of IC processing, including ‘bottom-up’ as well as ‘top-down’ processing, may reflect basal pathogenesis of various clinical representations of schizophrenia. However, the P100 latency difference between IC and RC was very small in the patient group. Rather, ‘cognitive’ in the Positive and Negative Syndrome Scale (PANSS) model of Bell et al. significantly correlated with P100 latencies for NC. Such an association between PANSS and NC processing, where the shape must be inferred with increased attentional demands and ‘top-down’ processing, indicates that the abnormality of schizophrenic patients’ preattentive process might be a problem of ‘top-down’ processing rather than ‘bottom-up’ processing.

Keywords:
Event-related potentials, Illusory contour, Schizophrenia, Bottom-up processing, Top-down processing
This content is only available via PDF.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.